Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean Infants

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 4

Conditions

Rotavirus Vaccines

Infections, Rotavirus

Treatments

Biological: Placebo

Biological: Rotarix ™

Study type

Interventional

Funder types

Industry

Identifiers

NCT00969228

112269

2015-001545-81 (EudraCT Number)

Details and patient eligibility

About

The aim of this study is to assess the immunogenicity, reactogenicity and safety of the human rotavirus (HRV) Rotarix ™ vaccine when administered in healthy infants aged approximately 6-12 weeks at the time of first vaccination.

Enrollment

684 patients

Sex

All

Ages

6 to 12 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Subjects who the investigator believes that their parents/guardians can and will comply with the requirements of the protocol should be enrolled in the study.
A male or female between, and including, 6 to 12 weeks of age at the time of the first dose of the vaccination.
Written informed consent obtained from the parents or guardians of the subject.
Healthy subjects as established by medical history and clinical examination before entering into the study.
Born after a normal gestation period of between 37 and 41 weeks + 6 days inclusive.
Subjects for whom the vaccination history is available from vaccination diary cards or medical charts.

Exclusion criteria

Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the dose of study vaccine, or planned use during the study period.
Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.
Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine with the exception of the routine infant vaccines.
Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.
Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Acute disease at the time of enrolment.
Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period.
Gastroenteritis (GE) within 7 days preceding the study vaccine administration.
Previous confirmed occurrence of RV GE.
Previous vaccination with rotavirus vaccine or planned use during the study period.